[{"id":"d1c65fef-f151-4887-8cfe-4cca4bc9b521","acronym":"","url":"https://clinicaltrials.gov/study/NCT03282396","created_at":"2021-01-18T16:12:27.906Z","updated_at":"2024-07-02T16:35:08.356Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma","source_id_and_acronym":"NCT03282396","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive • TP53 wild-type • KMT2D mutation • MYC positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-04-22"},{"id":"e089e3f8-f160-47a9-a0b8-746650c303a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861050","created_at":"2023-05-16T17:06:41.960Z","updated_at":"2024-07-02T16:35:30.746Z","phase":"Phase 1/2","brief_title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05861050","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression","tags":["TP53 • CDKN2A • CCND1 • KMT2D • NOTCH2 • SOX11 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(11;14) • KMT2D mutation • CCND1 expression • SOX11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-11-01"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"12441980-737d-4616-9bf1-f93f67db0099","acronym":"","url":"https://clinicaltrials.gov/study/NCT01665703","created_at":"2021-01-18T07:12:01.461Z","updated_at":"2024-07-02T16:36:36.476Z","phase":"","brief_title":"Imaging Correlates of Renal Cell Carcinoma Biological Features","source_id_and_acronym":"NCT01665703","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PBRM1 • KMT2D • HIF1A • SETD2 • MLL2","pipe":" | ","alterations":" KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression","tags":["PBRM1 • KMT2D • HIF1A • SETD2 • MLL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2021-01-07"},{"id":"8e96cc7a-6dec-4aa5-96fd-2012bb5fe9bb","acronym":"LUDOC","url":"https://clinicaltrials.gov/study/NCT02062697","created_at":"2021-01-18T09:30:05.355Z","updated_at":"2024-07-02T16:36:49.646Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","source_id_and_acronym":"NCT02062697 - LUDOC","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-25"}]